British-Swedish multinational pharmaceutical company, AstraZeneca, has put measures in place to begin distribution of its newly developed Covid-19 antibody treatment called AZD7442.
The drug has been clinically proven to be highly effective in the prevention of COVID-19 infections. Results from the Clinical trials show that patients injected with the antibody treatment, exhibit a high percentage of protection against coronavirus than patients who were given a placebo.
The result analysis confirmed that three months after the treatment was administered, the risk of having severe infections was reduced in patients by 77%.
Six months after, no severe cases of Covid-19 or deaths from the virus were recorded among patients who received the antibody treatment.
